ECSP24003913A - Virus recombinante aislado a base del virus de la gripe - Google Patents

Virus recombinante aislado a base del virus de la gripe

Info

Publication number
ECSP24003913A
ECSP24003913A ECSENADI20243913A ECDI202403913A ECSP24003913A EC SP24003913 A ECSP24003913 A EC SP24003913A EC SENADI20243913 A ECSENADI20243913 A EC SENADI20243913A EC DI202403913 A ECDI202403913 A EC DI202403913A EC SP24003913 A ECSP24003913 A EC SP24003913A
Authority
EC
Ecuador
Prior art keywords
virus
influenza virus
flu
recombinant
influenza
Prior art date
Application number
ECSENADI20243913A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Ekaterina Alekseevna Stepanova
Timur Mugdinovich Sheudzhen
Tatiana Urevna Ostroukhova
Aleksei Aleksandrovich Aleksandrov
Larisa Georgievna Rudenko
Irina Nikolayevna Isakova-Sivak
Viktoriia Arkadienva Matiushenko
Aleksandr Nikolaevich Doronin
Bogdan Olegovich Neterebskii
Dmitry Valentinovich Morozov
Sergei Andreevich Niskanen
Anna Konstantinovna Vladimirova
Iakov Iurevich Ustiugov
Original Assignee
Biocad Joint Stock Co
Federal State Budgetary Scient Institution Institute Of Experimental Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021121139A external-priority patent/RU2813150C2/ru
Application filed by Biocad Joint Stock Co, Federal State Budgetary Scient Institution Institute Of Experimental Medicine filed Critical Biocad Joint Stock Co
Publication of ECSP24003913A publication Critical patent/ECSP24003913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención está relacionada con los campos de la biotecnología, la inmunología, la virología, la genética y la biología molecular. Concretamente, se refiere a un ácido nucleico aislado que codifica un polipéptido recombinante para aumentar el título de los anticuerpos contra el virus de la gripe (variantes), un virus recombinante basado en el virus de la gripe para inducir la inmunidad específica contra el virus de la gripe y/o prevenir las enfermedades relacionadas con el virus de la gripe, una composición farmacéutica y una vacuna que incluyen el mencionado virus recombinante basado en el virus de la gripe, así como su uso para inducir la inmunidad específica contra el virus de la gripe y/o prevenir las enfermedades relacionadas con el virus de la gripe.
ECSENADI20243913A 2021-07-16 2024-01-16 Virus recombinante aislado a base del virus de la gripe ECSP24003913A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021121139A RU2813150C2 (ru) 2021-07-16 Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа

Publications (1)

Publication Number Publication Date
ECSP24003913A true ECSP24003913A (es) 2024-02-29

Family

ID=84919538

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20243913A ECSP24003913A (es) 2021-07-16 2024-01-16 Virus recombinante aislado a base del virus de la gripe

Country Status (6)

Country Link
EP (1) EP4370681A4 (es)
AR (1) AR126008A1 (es)
EC (1) ECSP24003913A (es)
JO (1) JOP20240009A1 (es)
TW (1) TW202306968A (es)
WO (1) WO2023287324A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7151163B2 (en) * 2003-04-28 2006-12-19 Sequoia Pharmaceuticals, Inc. Antiviral agents for the treatment, control and prevention of infections by coronaviruses
WO2004111081A2 (en) * 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
PL1697507T3 (pl) * 2003-12-02 2013-03-29 Pasteur Institut Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS
SG159542A1 (en) * 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US9757446B2 (en) * 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor
CN111217920B (zh) * 2020-03-10 2020-11-17 河北精硕生物科技有限公司 新冠病毒n-s优势表位融合蛋白、制备方法、应用，及表达蛋白、微生物、应用，试剂盒

Also Published As

Publication number Publication date
WO2023287324A1 (en) 2023-01-19
EP4370681A1 (en) 2024-05-22
AR126008A1 (es) 2023-08-30
EP4370681A4 (en) 2025-11-19
TW202306968A (zh) 2023-02-16
JOP20240009A1 (ar) 2024-01-16

Similar Documents

Publication Publication Date Title
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
CO2017007105A2 (es) Nuevos virus de tilapia
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
TW200732476A (en) Functional influenza virus like particles (VLPs)
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
CR20220138A (es) Composiciones y métodos para el tratamiento de infecciones virales
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
PE20181176A1 (es) Composiciones biofarmaceuticas
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MX2024004297A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
CY1118941T1 (el) Νεα συνθεση εμβολιου εναντι γριπης
PY2174368A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sars-cov-2 y/o la prevención de la infección por coronavirus relacionada con el sars-cov-2
CO2021008774A2 (es) Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
PY21111761A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sars-cov-2 y/o la prevención de la infección por coronavirus relacionada con el sars-cov-2
ECSP24003913A (es) Virus recombinante aislado a base del virus de la gripe
UY37198A (es) Vacuna universal para enfermedades virales
BR112018072729A8 (pt) sistema genético reverso do vírus da zica
PY2303105A (es) Virus recombinante aislado basado en el virus de la gripe para inducir una inmunidad especifica contra el virus de la gripe y/o prevenir enfermedades relacionadas con el virus de la gripe.-
BR112023004433A2 (pt) Ácido nucleico, vetor, segmento genômico viral, vírus, composição farmacêutica, método para induzir ou aumentar uma resposta imune contra o vírus influenza, vírus recombinante, método para induzir uma resposta imune em um sujeito em necessidade e polipeptídeo